Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. The key product candidate is Rigosertib which is a small molecule which blocks cellular signaling by targeting RAS effector pathways.